Equities analysts predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will report ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Syros Pharmaceuticals posted earnings per share of ($0.58) during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The company is expected to announce its next quarterly earnings report on Monday, March 11th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.85). For the next year, analysts anticipate that the firm will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.11) to ($1.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, November 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.02). The business had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.72 million.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Syros Pharmaceuticals by 10.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after buying an additional 7,062 shares during the period. MetLife Investment Advisors LLC boosted its position in Syros Pharmaceuticals by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock worth $242,000 after buying an additional 7,230 shares during the period. JPMorgan Chase & Co. boosted its position in Syros Pharmaceuticals by 2.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after buying an additional 8,286 shares during the period. Rhumbline Advisers boosted its position in Syros Pharmaceuticals by 87.6% during the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock worth $229,000 after buying an additional 10,494 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $119,000. Institutional investors own 61.26% of the company’s stock.
Syros Pharmaceuticals stock traded up $0.91 during trading hours on Friday, reaching $7.72. 3,035 shares of the stock were exchanged, compared to its average volume of 84,765. Syros Pharmaceuticals has a twelve month low of $6.25 and a twelve month high of $15.88. The company has a market capitalization of $229.19 million, a price-to-earnings ratio of -3.51 and a beta of 0.79.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
See Also: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.